【Lonza X DCB Biotech Industry Academy】Immunogenicity: An Essential Yet Often Overlooked Aspect of Drug Development
[Lonza X DCB Biotech Industry Academy]
Immunogenicity: An Essential Factor in Drug Development
With the growth of biologics, innovative therapies such as monoclonal antibodies, vaccines, and gene therapies are expanding rapidly. Compared to traditional small molecules, biologics offer better specificity and treatment flexibility, making them promising candidates for addressing hard-to-treat diseases. However, during development, immunogenicity presents a significant challenge.
Immunogenicity refers to the potential of biologics to trigger immune responses in the body, potentially leading to the production of anti-drug antibodies (ADAs) or neutralizing antibodies (NAbs). These responses can compromise therapeutic efficacy, reduce treatment continuity, and raise safety concerns. While the frequency and severity of immunogenicity vary by drug, its risk must be evaluated and managed during development.
This course invites Dr. Yvette Stallwood from the global biotech firm Lonza (UK), who will share her extensive practical experience and insights into immunogenicity evaluation and control.
📌 Key Topics Include
Overview of immunogenicity and its impact on drug development
Immunogenicity risk assessment strategies
Testing methodologies and associated challenges
Management and mitigation strategies
📆 Date & Time: May 23, 2025 (Friday), 13:00–17:00 (Check-in from 12:40)
📍 Location: Room E108, 1F, Building E, National Biotechnology Research Park
(No. 107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City)
📎 Registration Link: https://forms.gle/5hiCq71S6XMta4Y27
👩🏫 Speaker Introduction
Dr. Yvette Stallwood
17+ years of experience in biotech and biopharma development
Expert in immunology, molecular biology, and drug development
Senior Director, Early Development Services, Lonza Biologics (UK)
Led development of over 1,000 biologics from candidate discovery to commercialization
Collaborates closely with regulatory authorities in line with ICH safety guidelines
💰 Course Fee
Standard: NT$4,000
Early Bird: NT$2,000 (before May 18)
Special Bundle: NT$3,500 for both courses on May 23 (includes lunch)
🏦 Bank Transfer Info
Account Name: Development Center for Biotechnology
Bank: E.SUN Bank, Zhongxiao Branch
Bank Code: 807
Account Number: 005-004-0001772-3
※ Please pay after receiving the confirmation notice. Provide the last 5 digits of your transfer for verification.
📌 Important Notes
The academy reserves the right to adjust content, speakers, and venue. Unspecified matters may be updated anytime.
For a certificate of participation, please contact us via email after the course.
Contact: Academic Manager Ms. Lin (02)7700-3800 Ext.5283; rebecca206tw@dcb.org.tw
In case of force majeure (e.g., natural disasters) resulting in venue closure, the course will be rescheduled. Full refunds will be available for those unable to attend. Refund requests require a copy of the bankbook; refunds cannot be processed without it.
Immunogenicity: An Essential Factor in Drug Development
With the growth of biologics, innovative therapies such as monoclonal antibodies, vaccines, and gene therapies are expanding rapidly. Compared to traditional small molecules, biologics offer better specificity and treatment flexibility, making them promising candidates for addressing hard-to-treat diseases. However, during development, immunogenicity presents a significant challenge.
Immunogenicity refers to the potential of biologics to trigger immune responses in the body, potentially leading to the production of anti-drug antibodies (ADAs) or neutralizing antibodies (NAbs). These responses can compromise therapeutic efficacy, reduce treatment continuity, and raise safety concerns. While the frequency and severity of immunogenicity vary by drug, its risk must be evaluated and managed during development.
This course invites Dr. Yvette Stallwood from the global biotech firm Lonza (UK), who will share her extensive practical experience and insights into immunogenicity evaluation and control.
📌 Key Topics Include
Overview of immunogenicity and its impact on drug development
Immunogenicity risk assessment strategies
Testing methodologies and associated challenges
Management and mitigation strategies
📆 Date & Time: May 23, 2025 (Friday), 13:00–17:00 (Check-in from 12:40)
📍 Location: Room E108, 1F, Building E, National Biotechnology Research Park
(No. 107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City)
📎 Registration Link: https://forms.gle/5hiCq71S6XMta4Y27
👩🏫 Speaker Introduction
Dr. Yvette Stallwood
17+ years of experience in biotech and biopharma development
Expert in immunology, molecular biology, and drug development
Senior Director, Early Development Services, Lonza Biologics (UK)
Led development of over 1,000 biologics from candidate discovery to commercialization
Collaborates closely with regulatory authorities in line with ICH safety guidelines
💰 Course Fee
Standard: NT$4,000
Early Bird: NT$2,000 (before May 18)
Special Bundle: NT$3,500 for both courses on May 23 (includes lunch)
🏦 Bank Transfer Info
Account Name: Development Center for Biotechnology
Bank: E.SUN Bank, Zhongxiao Branch
Bank Code: 807
Account Number: 005-004-0001772-3
※ Please pay after receiving the confirmation notice. Provide the last 5 digits of your transfer for verification.
📌 Important Notes
The academy reserves the right to adjust content, speakers, and venue. Unspecified matters may be updated anytime.
For a certificate of participation, please contact us via email after the course.
Contact: Academic Manager Ms. Lin (02)7700-3800 Ext.5283; rebecca206tw@dcb.org.tw
In case of force majeure (e.g., natural disasters) resulting in venue closure, the course will be rescheduled. Full refunds will be available for those unable to attend. Refund requests require a copy of the bankbook; refunds cannot be processed without it.
